Altshock-2 Through a Regional Lens: IABP in HF-CS | JACC Baran
Hosts Mitsuaki Sawano, MD, and co-host Satoshi Shoji, MD, welcome regional associate editor Kentaro Ejiri, MD, for his debut appearance on the JACC: Baran Journal Club. Dr. Ejiri presents insights on ...
6 Mai 202546min
Disentangling the Impact of Adiposity From Insulin Resistance in HFpEF | JACC Deep Dive
In a Deep Dive in our May 13 issue, Editor-in-Chief Harlan Krumholz, MD, SM, FACC, discusses a study led by Barry Borlaug that investigates whether excess weight or metabolic dysfunction has a greater...
6 Mai 20256min
Revisiting the SUMMIT Trial | JACC Deep Dive
This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardles...
6 Mai 20255min
JACC Editor's Page: May 13, 2025
In a time of rising global tensions, JACC reaffirms its commitment to science as a unifying, borderless force—advocating for truth, equity, and collaboration to improve health worldwide. By fostering ...
5 Mai 20257min
Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results from ORBITA-2 | JACC
In this podcast, Dr. Valentin Fuster discusses a groundbreaking study from the Orbiter 2 trial, which explores how dobutamine stress echocardiography (DSE) can predict the efficacy of percutaneous cor...
5 Mai 20259min
May 13, 2025 Issue Summary | JACC
In this episode, Dr. Valentin Fuster, provides a concise summary of the May 13, 2025 issue. He discusses four original studies on key cardiovascular topics, including the impact of chronic kidney dise...
5 Mai 202524min
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction and Obesity: the SUMMIT Trial | JACC
In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF)...
5 Mai 20258min
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: the EMPEROR Program | JACC
In this podcast, Dr. Valentin Fuster explores a study on the effects of SGLT2 inhibitors, like empagliflozin, on erythropoiesis and iron mobilization in heart failure patients. The research reveals ho...
5 Mai 20259min
